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Triumph and Tragedy of 21st Century 
Tuberculosis Drug Development
Guy Thwaites, F.R.C.P., and Payam Nahid, M.D., M.P.H.
Since the discovery of the first antituberculosis 
drugs 75 years ago, the pursuit of a short, effec-
tive, and affordable regimen that has acceptable 
side effects and is capable of curing most pa-
tients most of the time has been a major public 
health priority. Such a “pan-tuberculosis” regi-
men is seen by many as essential in reducing the 
global tuberculosis burden.1
The successful development of two new anti-
tuberculosis drugs — bedaquiline and pretoma-
nid — represents an important step forward in 
the pursuit of pan-tuberculosis regimens fit for the 
21st century. Conradie and colleagues now report 
in the Journal that when this all-oral regimen was 
combined with a third drug — linezolid, repur-
posed from its licensed indication for gram-
positive bacterial infections — and given for 26 
to 39 weeks to patients with extensively drug-
resistant or complicated multidrug-resistant tu-
berculosis, it produced a favorable outcome in 98 
of 109 patients (90%) at 6 months after the end 
of treatment.2 Cure rates for extensively drug-
resistant tuberculosis were less than 50% before 
the advent of new drugs.3 Therefore, this is a 
triumph, and the authors are to be congratulated 
for their vision and courage in tackling the most 
difficult-to-treat forms of tuberculosis.
The tragedy being confronted, however, is the 
overlapping realities of the persisting need for 
new regimens and the spectacular inadequacy of 
support for their development and the tools 
needed for their effective use in the field. Our 
current tuberculosis regimen was the product of 
a remarkable series of global, iterative, random-
ized, controlled trials conducted between 1947 
and 1980.4 The resulting “short-course chemo-
therapy” was an oral regimen, containing rifam-
pin, isoniazid, and pyrazinamide, that cured the 
large majority of people with tuberculosis if it 
was taken for 6 months. This regimen, despite 
known toxicities, has produced extraordinary 
gains, curing approximately 58 million people 
since the year 2000.5 However, 30 years of its 
global use has revealed the serious limitations of 
depending on a single, one-size-fits-all regimen 
to treat a challenging infectious disease.6 Pre-
dictable toxicities and the development of resis-
tance are directly relevant to ongoing efforts to 
develop other regimens,7 including the new 
regimen studied by Conradie et al.
During the early global adoption of rifampin-
based short-course chemotherapy, the possibility 
that resistance would become a barrier to ending 
the epidemic was considered unlikely. As a result, 
the development of accessible and affordable 
laboratory tools for the detection of drug resis-
tance was not prioritized. Thus, when resistance 
did inevitably emerge, the tools to detect and 
manage it were too inefficient, too costly, and too 
far from the clinic to halt the spread of rifampin 
resistance. The acquisition of resistance is also a 
risk for the bedaquiline–pretomanid–linezolid 
regimen. Conradie reports one patient who had 
a relapse caused by bacteria with reduced sus-
ceptibility to bedaquiline. When this evidence is 
considered together with other reports of pri-
mary resistance to bedaquiline,8 along with the 
described toxicities of linezolid, the need for 
monitoring of the QT interval, and the residual 
uncertainty about hepatotoxicity of pretomanid,9 
it suggests a risk of going back to where we 
started: a situation in which a pan-tuberculosis 
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regimen with known toxicities that are likely to 
result in pauses in or discontinuation of treat-
ment is sent to the field without adequate tools 
for monitoring resistance.
The other major tragedy is that every year 
tuberculosis still affects approximately 10 mil-
lion people and kills 1.5 million.5 In light of 
these figures, we should not be dependent on 
one small, single-group, single-country study for 
evidence of the efficacy of the newest tuberculo-
sis regimen. The study was rigorously conducted 
and laudably designed to report on definitive 
outcomes of durable cure and relapse; however, 
such approaches for the development of tubercu-
losis regimens do not correspond with the mag-
nitude of the problem. Tuberculosis does not 
present insurmountable hurdles for the conduct 
of clinical trials. Even the creation of multidrug 
regimens with new agents from different devel-
opers is feasible, as evidenced by the recent his-
tory of treatment for human immunodeficiency 
virus infection and hepatitis C, both of which 
have new regimens developed and defined 
through multiple large trials. In contrast and 
tragically, the majority of evidence available to 
the World Health Organization in 2020 as it 
formulates treatment guidelines for drug-resis-
tant tuberculosis comes from noncomparative 
or observational studies.10,11 Such studies should 
serve as the adjunct to an evidence base of robust 
randomized, controlled clinical trials, rather than 
as its leading edge.
A rejuvenated program of innovative phase 2 
and phase 3 clinical trials of new drugs and 
regimens, in conjunction with continued invest-
ment in tools for detecting and monitoring resis-
tance, is required worldwide. It will take substan-
tially greater investment and coordinated forms 
of collaboration among sponsors, industry, aca-
demic partners, and policy decision makers to 
develop and implement new evidence-based regi-
mens that are fitting for a disease that has killed 
hundreds of millions of people. Until that hap-
pens, if the current inadequate investment path 
is held, history is bound to repeat itself — and 
for all the jubilation that comes with developing 
a new effective regimen, there will be more trag-
edy yet to come.
Disclosure forms provided by the authors are available with 
the full text of this editorial at NEJM.org.
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Vaping-Induced Acute Lung Injury
David C. Christiani, M.D., M.P.H.
A number of environmental agents are known to 
cause acute or subacute inhalation injury to the 
lung parenchyma. Indeed, emergency response 
guidelines for medical personnel describe toxic 
inhalation pneumonitis as a heterogeneous group 
of chemically induced injuries to the lung paren-
chyma as well as to the upper respiratory tract. 
The manifestations of such injury depend on the 
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